China in the Global Healthcare Ecosystem

Strong Venture Growth Drives Innovation

Follow @SVB_Financial  Engage #SVBHealthcare
China’s innovation economy is an amazing success story, and Silicon Valley Bank is proud to be part of it — since 1999, when we established our first presence in Shanghai. In 2012, we built on that success when we established SPD Silicon Valley Bank (SSVB), a joint venture with the Shanghai Pudong Development Bank and the first technology and innovation bank of its kind in China.

This dynamic partnership, which now includes branches in Beijing and Shenzhen, has grown to serve Chinese founders and innovation companies with core banking products, including RMB-denominated accounts, while helping promote collaboration and investment by US and EMEA companies in the Chinese innovation economy. In the life science and healthcare space, SVB and SSVB together serve more than 3,500 clients globally, with the shared mission to increase our clients’ probability of success and be the most sought-after partner globally for innovators, enterprises and investors.

Underscoring this commitment, I’m pleased to share this inaugural China healthcare report, produced in collaboration with SSVB. The report highlights China and cross-border trends from SVB’s rich proprietary intelligence, as well as insights from interviews with more than two dozen companies and investors in the US, Shanghai and Beijing. It comes six years after we launched the Healthcare Capital & Connections Summit, a global cross-border healthcare conference in Shanghai, to nurture US, EMEA and China collaborations and partnerships.

While the global COVID-19 pandemic continues to dominate headlines, the US and China — the world’s two largest healthcare markets — are working to solve enormous healthcare challenges. On the global healthcare stage, biopharma is consistently the leading subsector in terms of invested capital. China remains a strong contributor and value driver due to its skilled workforce and growing consumer demand to address the healthcare priorities of its growing middle class and aging population.

While we’re faced with many uncertainties in 2020, the fundamentals for healthcare and the life sciences remain strong, and the tightknit community that composes our industry is positioned to navigate the path forward — together. Healthcare and technology will continue to converge on a global scale, and with SVB’s global footprint and position at the center of the innovation ecosystem, we’re well prepared to help you succeed. The future of truly disruptive healthcare innovation is here — and it’s global.
Table of Contents

4 Executive Summary
5 Macro
8 Venture-backed Healthcare Investments
21 Venture-backed Public Healthcare Investments
25 China Healthcare Outlook
Strong Venture Growth Drives Innovation

The global* healthcare innovation ecosystem has raised $35B in 2020, led by the US with $22.6B (65%), followed by China with $6.7B (19%) and Europe with $5.5B (16%). Despite financial headwinds from the COVID-19 pandemic, there have been 81 $100M+ global,* venture-backed healthcare rounds, nearly tripling 2019’s totals during the same period.

In 2020, US healthtech overtook US biopharma in terms of deal count (301 deals vs. 261 deals); however, biopharma still reigns in terms of total invested capital ($10.6B compared to healthtech’s $7B). In China, biopharma has maintained the lead over other sectors on both fronts, with 80 deals and $3.4B invested capital. China’s dx/tools is second with $1.8B invested across 60 deals.

COVID-19 has not thwarted private, venture-backed healthcare companies from raising money and closing active deals. In 2020, New York City (US) and Shanghai (CN) have led the world in deals, with healthcare companies in each city completing a total of 71 deals worth $2B. The three remaining top five cities are San Francisco (US) with 64 deals ($2.5B), Cambridge, Mass. with 51 deals ($2.6B), and Beijing (CN) with 43 deals ($729M).

Likewise, geopolitical and macroeconomic forces have not inhibited cross-border activity, as 2020 has seen an uptick in China-based investors participating in US and European company deals. In fact, these syndicated investments have already totaled $5.6B, up from 2019’s $3.5B. Cross-border deals have been driven largely by investors with healthcare interests, as China’s BAT has substantially decreased its investment into the US since 2019.

This year, China has seen 22 venture-backed companies go public ($4.2B total raised IPO proceeds), with an astounding 18 (82%) having a $1B+ market cap. The biopharma sector dominates the public markets, accounting for 13 (59%) of the 22 IPOs in 2020. The strong post-IPO performance of companies on local mainland China and Hong Kong markets have made them attractive options for entrepreneurs seeking an exit opportunity. This year, 12 companies (55% of 2020 IPOs) have gone public on the mainland China exchanges, ChiNext Market or STAR Market, raising combined IPO proceeds of $2.1B (54% of total).

---

*Global is defined as only the US, Europe, mainland China and Hong Kong. **Top five diseases are defined as diabetes, oncology, cardiovascular, neurological and respiratory disorders. BAT defined as Baidu, Alibaba and Tencent. Financing data include private financings by venture-backed companies that are based in mainland China, Hong Kong, US, and Europe. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20 with any previous year comparison being made through an analogous time frame. Market cap was calculated as of 8/31/20. Source: PitchBook, Capital IQ, SVB proprietary data and SVB analysis.
Macro

Incentive and Opportunity for Innovation in China
China’s Government Incentivizes Innovation

Over the last decade, China’s government has introduced a plethora of healthcare system reforms, ranging from increasing R&D funding and revamping market authorization requirements to accelerating clinical trial processes and overhauling distribution channels. This government push took off in 2015 with the Chinese government’s Made in China 2025 initiative. The goal of MiC2025 was to transform China into a global R&D and manufacturing powerhouse, allocating over $1.2T to encourage on-the-ground, in-house innovation across all healthcare sectors. Since MiC2025’s launch, a series of similar initiatives has followed, each striving to pump capital into China’s healthcare innovation economy while increasing the speed and capacity of China’s development and distribution processes.

In 2020, China kicked off the year on a high note, with the NMPA approving the First Class III AI-enabled medical device developed by Deep Vessel. However, soon thereafter, turbulence from the COVID-19 pandemic resulted in China’s first GDP contraction (-6.8%) in over a decade. Despite this setback, China still predicts a positive GDP for 2020 (+1.2%) and has pledged $2B over two years to help with the global COVID-19 response.

Timeline of China’s Marquee Healthcare Initiatives and Events 2016–2020

- **Healthy China 2030** aims to create a $2.1T healthcare system
- **4+7 Drug Procurement Reform** lowers generic drug pricing and establishes quality consistency
- **Telemedicine reimbursement** approved for provider consultations
- **NDA streamlines clinical trial process to make it more efficient**
- **Provincial governments establish online regulatory platforms to accelerate market access of internet-based hospitals**

**October 2016**
- CFDA creates “fast-track” review for the approval of drugs addressing urgent clinical needs

**December 2017**
- **Healthy China 2030**

**June 2018**
- **4+7 Drug Procurement Reform**

**May 2019**
- **Telemedicine reimbursement**

**August 2019**
- **NDA streamlines clinical trial process to make it more efficient**

**August 2020**
- **Provincial governments establish online regulatory platforms to accelerate market access of internet-based hospitals**

---

NDA defined as New Drug Application.

Source: News articles, China Food and Drug Administration (CFDA), National Medical Products Administration (NMPA).
China’s Healthcare System Directs Global Spotlight

With 1.4 billion potential consumers, significant market opportunity and a budding cohort of talent, some of the world’s largest healthcare companies are ramping up their bets on China’s healthcare market, establishing joint ventures and making investments into the nation’s healthcare ecosystem.

Compared to the US and Europe, our 2030 projections name China as having the largest patient population (1.2B) for all top disease indications across age groups.

To further healthcare players’ desire to tap into the auspicious market, China’s population is aging at a rate that few countries can match. Its elderly population (aged 65+) has risen from 7.9% in 2009 to 11.4% in 2019 and is projected to reach 15.9% by 2030.

Compounding matters, China’s hospital systems have struggled to keep up with the growing demand for healthcare services. China has 1.8 doctors for every 1,000 patients whereas the US and UK have 2.4 and 2.8, respectively.

The next few years will serve as an important opportunity for China’s innovation economy to develop solutions to aid the strained system and establish itself as a competitive alternative or complement to the country’s larger healthcare providers.

Projected 2030 Global Disease Prevalence
China, Europe and United States

Venture-backed Healthcare Investments
China and Cross-border
Led by Biopharma and Dx/Tools, 2020 $s Already at 2019’s Level

While 2017’s first three quarters of funding were relatively slow, the year ended with healthtech’s Ping An Healthcare and Technology’s staggering $2.2B deal in December. Dx/Tools also netted three $100M+ deals in Q4.

This momentum carried through to 2018, the breakout year for China’s healthcare market. 2018’s historic $8.1B in venture-backed healthcare was primarily fueled by two marquee events: Ping An Medical and Healthcare Management’s $1.2B round, led by SoftBank, and WeDoctor’s $500M round, co-led by AIA Qiming and NWS Holdings.

2019 funding was up slightly from 2017 but down nearly 30% from 2018. This decrease in funding can largely be attributed to a drop-off in biopharma and healthtech investment, as dx/tools and device funding remained relatively constant.

Q2 2020 sported the second-largest quarter investment total to date for venture-backed healthcare companies in China (led by MGI’s $1B deal and Mabwell’s $278M deal), despite financial market unease and potential company setbacks due to the COVID-19 pandemic. Notably, this resilience was also seen in the US venture-backed healthcare market, which showed a 32% increase in total 1H 2020 funding when compared to its 2H 2019 counterpart. On the other hand, Europe saw a -14% investment decrease during the same period.

<table>
<thead>
<tr>
<th>Sectors ($M)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopharma</td>
<td>$1,146</td>
<td>$3,709</td>
<td>$2,500</td>
<td>$3,448</td>
</tr>
<tr>
<td>HealthTech</td>
<td>$3,370</td>
<td>$3,297</td>
<td>$1,588</td>
<td>$610</td>
</tr>
<tr>
<td>Device</td>
<td>$418</td>
<td>$350</td>
<td>$589</td>
<td>$871</td>
</tr>
<tr>
<td>Dx/Tools</td>
<td>$729</td>
<td>$767</td>
<td>$1,111</td>
<td>$1,810</td>
</tr>
<tr>
<td>Total</td>
<td>$5,663</td>
<td>$8,123</td>
<td>$5,788</td>
<td>$6,739</td>
</tr>
</tbody>
</table>

Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. *2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.
Four $1B+ Healthcare Companies in China, on Par with Europe

This list contains the highest-valued private companies since 2019, all with publicly disclosed post-money valuations of $300M+.

Since 2019, four companies in China have achieved the coveted $1B+ post-money private valuation — on par with Europe but still behind the US’s 18.

The median round size for this group was $82M, with a pre-money valuation of $494M. Two of these companies have gone public on the Shanghai Stock Exchange: BrightGene (11/2019) and Sino Biological (6/2020). BrightGene priced its IPO at $1.82 per share and is now trading up +368% with a $3.5B market cap. Sino Biological priced its IPO at $3.69 per share and is now trading up +212% with a $5B market cap.

The ubiquitous nature of healthcare pain points has given rise to doppelgängers across China, the US and Europe. For example, Tencent Trusted Doctors (healthtech), who focuses on providing care outside of the hospital, is comparable to the US’s OneMedical (Nasdaq: ONEM, $1.97B post) and the UK’s Babylon Health ($2B post on a $550M round). Likewise, MicroPort (device), who focuses on structural heart disease, is comparable to the US’s Foldax ($150M post on a $20M round) and Ionetix ($131M post on a $61M round).
Biopharma and Series B/Later-Stage Deals Draw the Most Interest

In the past three years, there have been an impressive 57 $100M+ financings in the private venture-backed China healthcare market — more than Europe’s 21 but still shy of the US’s incredible 155. In China, these mega-rounds were syndicated with corporate investors 30% of the time.

The most active investors listed on this page prefer to invest in Series B or later-stage financings approximately 60% of the time, with biopharma drawing the most total investments by venture capitalists located in China and abroad.

On the other hand, the corporates on this page have preferred to invest in healthtech (33 deals) and dx/tools (24 deals) over biopharma (19 deals) and device (7 deals). Together, they have led 18 healthtech deals, 8 dx/tools and 5 biopharma and device deals.

The top three most active investors in 2020 during the COVID-19 pandemic — Qiming Venture Partners (14 deals), Sequoia Capital China (11 deals) and Hillhouse Capital Group (eight deals) — have made a combined 19 investments in the biopharma sector.

---

**Most Active Investors**

**Number of Deals (Mainland China and Hong Kong, 2018–2020)**

<table>
<thead>
<tr>
<th>Venture Capital (HQ’d in China / HK)</th>
<th>Venture Capital (HQ’d outside of China / HK)</th>
<th>Corporate Investor</th>
</tr>
</thead>
<tbody>
<tr>
<td>59 QIMING</td>
<td>11 FPRIME</td>
<td>17</td>
</tr>
<tr>
<td>35 SEQUOIA CAPITAL</td>
<td>11 OrbiMed</td>
<td>16</td>
</tr>
<tr>
<td>27 Lilly Asia Ventures</td>
<td>8 EIGHT ROADS</td>
<td>13</td>
</tr>
<tr>
<td>23 LEGEND CAPITAL</td>
<td>7 ARCH VENTURE PARTNERS</td>
<td>12</td>
</tr>
<tr>
<td>22 弘晖资本 (Highlight Capital)</td>
<td>6 DECHENG CAPITAL</td>
<td>12</td>
</tr>
<tr>
<td>22 纽威资本 (Emerging Partners)</td>
<td>6 EMERGING PARTNERS</td>
<td>12</td>
</tr>
<tr>
<td>22 深圳市创新投资集团有限公司 (SVB CAPITAL GROUP CO., LTD)</td>
<td>6 SOUSV</td>
<td>11</td>
</tr>
<tr>
<td>21 IDG Capital</td>
<td>5* VIVO CAPITAL</td>
<td>9</td>
</tr>
</tbody>
</table>

*Additional investors have the same number of deals but are not included because of space limitations. 2020 financing data are compiled through 8/31/20. Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. Corporate parent and corporate venture investment are combined under Corporate Investor. Source: PitchBook, SVB proprietary data and SVB analysis.
Shanghai Ties San Francisco; Six $1B+ Regions for HC Investments

Shanghai dominates China’s healthcare funding with $7.2B raised from 2018–2020. For perspective, San Francisco — the second highest-funded city in the world in terms of venture-backed healthcare investment (second only to Cambridge, Mass.) — raised $7.3B during this same period. Over 60% of Shanghai’s healthcare investment has gone toward biopharma, followed by healthtech (27%), device (7%) and dx/tools (6%).

Beijing trails Shanghai in overall funding and deals; however, the city still boasts relatively high investment numbers. For example, Beijing’s $3.7B in funding is comparable to the sum of both France ($2.3B) and Germany’s ($1.7B) venture-backed investment. Unlike Shanghai, Beijing’s investment favors healthtech and dx/tools, with 39% and 28% of the city’s healthcare funding going toward each sector, respectively. Biopharma tracks closely behind at 26%, followed by device at 7%.

Notably, the Guangdong province has seen a recent shift from backing healthtech companies to primarily funding dx/tools startups. In 2018, dx/tools received just 16% of the province’s funding. In 2019–2020, dx/tools skyrocketed to comprising 68% of the province’s investment. MGI Tech’s $1B deal in 2020 is a large contributor to this jump in sector funding.
China Biopharma 2nd in the World to US; Oncology/Platform Dominate

Over the last three years, biopharma has led China’s venture-backed healthcare financings, attaining an impressive $9.7B. China is also the second-largest source of biopharma funding in the world (behind the US), surpassing the UK by more than fourfold.

In 2018 alone, China saw three $250M+ deals: Genor Biopharma (platform), Brii Biosciences (platform) and CStone Pharmaceuticals (oncology), two of which had at least one cross-border investor.

While 2018’s $3.7B raised is China’s largest biopharma funding YTD, 2020 is steadily encroaching on that record. In Q2 2020 alone, China’s venture-backed biopharma companies set a quarterly record of $1.5B in financings, led by Mabwell’s (auto-immune) $278M Series A.

From a geographic standpoint, Shanghai dominates year over year. In 2019, the city accounted for more than half of the country’s entire biopharma funding; 2018 and 2020 saw 45% and 40%, respectively. Similarly, the city typically comprises more than one-third of all annual biopharma deals.

Of note, several China-based biopharma startups have aided in COVID-19 research. For example, Livzon MABP harm (platform), who raised a $50M round in 2018, is working on COVID-19 tests.

### Biopharma Deals by Top Indications

- **Oncology**: 118 deals, $4.8B
- **Platform**: 100 deals, $3.4B
- **Metabolic**: 9 deals, $234M
- **Anti-Infective**: 8 deals, $198M
- **Auto-Immune**: 7 deals, $576M

<table>
<thead>
<tr>
<th>Indication</th>
<th>Deals</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>118</td>
<td>$4.8B</td>
</tr>
<tr>
<td>Platform</td>
<td>100</td>
<td>$3.4B</td>
</tr>
<tr>
<td>Metabolic</td>
<td>9</td>
<td>$234M</td>
</tr>
<tr>
<td>Anti-Infective</td>
<td>8</td>
<td>$198M</td>
</tr>
<tr>
<td>Auto-Immune</td>
<td>7</td>
<td>$576M</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>$3.7B (105)</td>
<td>$1.0B</td>
<td>$0.8B</td>
<td>$1.2B</td>
</tr>
<tr>
<td>2019</td>
<td>$2.5B (101)</td>
<td>$0.6B</td>
<td>$1.2B</td>
<td>$0.7B</td>
</tr>
<tr>
<td>2020</td>
<td>$1.3B</td>
<td>$1.5B</td>
<td>$0.7B</td>
<td>$0.7B</td>
</tr>
</tbody>
</table>

2018–2020 Deals

- **>250M**
  - **Brii Biosciences**
  - **Mabwell**

- **$150M to $250M**
  - **Akoso Bio**
  - **Henlius**

- **$125M to $150M**
  - **Akeso Bio**
  - **Linetti Biotech**

Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.
2018 Financings Set China Record; Shanghai and Beijing Share Lead

As with biopharma, China’s healthtech market ranks second in the world (behind the US) in terms of venture capital (VC) raised. In 2018, healthtech funding saw a significant surge, stemming from Ping An Medical and Healthcare Management’s (alternative care) $1.2B deal and WeDoctor’s (alternative care) $500M financing. Ping An’s $1.2B deal is the largest alternative care deal the global* healthtech sector has ever seen.

Interestingly, China’s healthtech funding dropped in 2019 (-45%) and continued to plunge in 2020 (-64%), while both the US and Europe saw increases in funding year-over-year. Two possible explanations for the cooling of investors’ activity in the sector are the high valuations and lack of notable exits for China-based healthtech companies.

While provider operations has seen more deals than any other healthtech sector, alternative care companies have received more funding. The median later-stage** deal size for alternative care deals is $30M whereas for provider operations it is half, or $15M.

Both Beijing and Shanghai are neck-and-neck in terms of healthtech deals and dollars across China. Over the last three years, Shanghai has comprised 35% of China’s healthtech funding in comparison to Beijing’s 27%. On the other hand, Beijing has housed 36% of China’s healthtech companies that closed deals in 2018–2020. Only 25% of these companies were headquartered in Shanghai.

---

2020 Financing

*Global is defined as only the US, Europe, mainland China and Hong Kong. **Later-stage defined as any round that occurs after a first-round institutional or corporate venture investment that is greater than or equal to $2M. Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.
Q3 2020 Totals Break Previous Annual Investment Records in China

Compared to the US and European countries, China ($1.8B) ranks second in device funding, trailing behind the US ($10.6B) but undoubtedly eclipsing France ($512M) and the UK ($456M), which are ranked third and fourth in global* device financings, respectively.

The median deal size for later-stage** cardiovascular deals is more than double that of surgical device deals: $33M vs. $14M, respectively. Interestingly, in the US, these comparable data are remarkably smaller. The median later-stage cardiovascular deal is $16M, and surgical is $10M.

From a geographic standpoint, Shanghai startups consistently receive one-quarter of China’s device funding, which is the largest average percentage of all of China’s cities and provinces. That said, in 2020, the Anhui province accounted for more than 50% of China’s device funding, with Peijia’s $150M deal contributing significantly to this shift.

Notably, 2020 funding has already surpassed that of 2018 and 2019’s annual investment totals, designating 2020 as the reigning year for China’s device funding, despite still having Q4 to go. Two companies, Peijia Medical ($150M) and MicroPort ($131M), have breached the $100M milestone in 2020. Both are focusing on cardiovascular solutions.

Device Deals by Top Indications
Mainland China and Hong Kong
2018–2020

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>53</td>
<td></td>
<td>$790M</td>
</tr>
<tr>
<td><strong>Surgical</strong></td>
<td>32</td>
<td></td>
<td>$198M</td>
</tr>
<tr>
<td><strong>Platform</strong></td>
<td>19</td>
<td></td>
<td>$112M</td>
</tr>
<tr>
<td><strong>Imaging</strong></td>
<td>15</td>
<td></td>
<td>$86M</td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td>12</td>
<td></td>
<td>$58M</td>
</tr>
</tbody>
</table>

2018–2020 Deals

- >100M
  - MicroPort
  - Aohua
  - Peijia
  - AOBO

- $25M+ to $100M
  - FitSAMO
  - SinoCardio
  - Hygea
  - MEDTRUM

2020 Financing

Total $ and (Deals)
Mainland China and Hong Kong

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>$350M (76)</td>
<td>$589M (77)</td>
<td>$872M (54)</td>
</tr>
<tr>
<td><strong>Surgical</strong></td>
<td>$127M</td>
<td>$161M</td>
<td>$241M</td>
</tr>
<tr>
<td><strong>Platform</strong></td>
<td>$127M</td>
<td>$91M</td>
<td>$504M</td>
</tr>
<tr>
<td><strong>Imaging</strong></td>
<td>$101M</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td>$100M</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Global is defined as only the US, Europe, mainland China and Hong Kong. **Later stage defined as any round that occurs after a first-round institutional or corporate venture investment that is greater than or equal to $2M. CF PharmTech closed two rounds in 2020 ($89.9M on 1/2/2020 and $50.8M on 7/2/2020). Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.
3-Year Funding Reaches $3.7B, Led by MGI’s $1B Giga-Round in 2020

Once again, China surpassed Europe’s top-funded countries to seal its second-place seat in dx/tools financings. Aside from the US ($11.7B), China ($3.7B) is the only other country to break the $1B funding glass ceiling during the 2018–2020 period.

In addition, dx/tools has seen a massive shift in funding based on geography. In 2018, Beijing-based dx/tools companies accounted for 65% of China’s overall dx/tools funding. However, in 2019, that percentage dropped to 30%; in 2020, it fell to just 10%.

At a high level, Beijing seemingly went from being the dx/tools hub to being one of the sector’s lesser-funded cities, with Guangdong taking Beijing’s seat at the head of the dx/tools funding table, raking in 61% of dx/tools funding in 2020. However, after removing Guangdong’s $1B deal raised by MGI (R&D tools), the largest dx/tools deal ever recorded globally,** Beijing still emerges as the leader in housing the biggest contingent of dx/tools deals and dollars over the last three years.

Notably, 17 China-based dx/tools companies are developing solutions to aid in the fight against COVID-19. This cohort has raised $1.6B over the last three years.

**Globally is defined as only the US, Europe, mainland China and Hong Kong. Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.
China’s Cross-Border Healthcare Investments Shoot Up in 2020

From Q1 2017 to Q4 2017, the total number of US and European financings syndicated with China-based investors increased by 140%. While Q4 2018 to Q4 2019 saw a notable decline in deals syndicated with China-based investors, this decrease mirrored China’s overall 2019 funding drop. Therefore, it is more likely that 2019 was simply a down year rather than geopolitical factors being at the root cause.

In 2020, both deal count and financing totals were up, with Q1 2020 exhibiting the highest deal and dollar numbers on record for syndicated China investments and Q3 2020 expected to be the second highest cross-border funding quarter to date.

China-based investors elect to invest most heavily in cross-border biopharma deals. In fact, this trend nearly translates to quarter over quarter with one exception. In Q4 2017, dx/tools received more funding due to China-based investors participating in GRAIL’s $1.2B financing.

While 2018 still holds the crown for most deals with China-based syndicated investment (113 deals), 2020 has already stolen the title for sheer funding. The total funding for US and European deals syndicated with China-based investors in 2020 amounts to $5.6B. 2018’s annual total was $4.3B, and 2019’s was $3.5B.

Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Investor HQ defined from primary investor HQ from PitchBook. Dates of financing rounds subject to change based on add-on investments. *2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.

---

China’s Syndicated Activity into VC-Backed Companies US and Europe 2017–2020

<table>
<thead>
<tr>
<th>Sectors ($M)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopharma</td>
<td>$1,232 / $18</td>
<td>$1,250</td>
<td>$1,708 / $271</td>
<td>$1,979</td>
</tr>
<tr>
<td>Dx/Tools</td>
<td>$1,925 / $10</td>
<td>$1,935</td>
<td>$1,163 / $105</td>
<td>$1,268</td>
</tr>
<tr>
<td>HealthTech</td>
<td>$387 / $5</td>
<td>$392</td>
<td>$248 / $30</td>
<td>$278</td>
</tr>
<tr>
<td>Device</td>
<td>$84 / $18</td>
<td>$102</td>
<td>$710 / $110</td>
<td>$820</td>
</tr>
<tr>
<td>Total</td>
<td>$3,628 / $51</td>
<td>$3,679</td>
<td>$3,829 / $516</td>
<td>$4,345</td>
</tr>
</tbody>
</table>

---

China’s Cross-Border Healthcare Investments Shoot Up in 2020

From Q1 2017 to Q4 2017, the total number of US and European financings syndicated with China-based investors increased by 140%. While Q4 2018 to Q4 2019 saw a notable decline in deals syndicated with China-based investors, this decrease mirrored China’s overall 2019 funding drop. Therefore, it is more likely that 2019 was simply a down year rather than geopolitical factors being at the root cause.

In 2020, both deal count and financing totals were up, with Q1 2020 exhibiting the highest deal and dollar numbers on record for syndicated China investments and Q3 2020 expected to be the second highest cross-border funding quarter to date.

China-based investors elect to invest most heavily in cross-border biopharma deals. In fact, this trend nearly translates to quarter over quarter with one exception. In Q4 2017, dx/tools received more funding due to China-based investors participating in GRAIL’s $1.2B financing.

While 2018 still holds the crown for most deals with China-based syndicated investment (113 deals), 2020 has already stolen the title for sheer funding. The total funding for US and European deals syndicated with China-based investors in 2020 amounts to $5.6B. 2018’s annual total was $4.3B, and 2019’s was $3.5B.

Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Investor HQ defined from primary investor HQ from PitchBook. Dates of financing rounds subject to change based on add-on investments. *2020 numbers through 8/31/20. Source: PitchBook, SVB proprietary data and SVB analysis.

---

China’s Syndicated Activity into VC-Backed Companies US and Europe 2017–2020

<table>
<thead>
<tr>
<th>Sectors ($M)</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopharma</td>
<td>$1,232 / $18</td>
<td>$1,250</td>
<td>$1,708 / $271</td>
<td>$1,979</td>
</tr>
<tr>
<td>Dx/Tools</td>
<td>$1,925 / $10</td>
<td>$1,935</td>
<td>$1,163 / $105</td>
<td>$1,268</td>
</tr>
<tr>
<td>HealthTech</td>
<td>$387 / $5</td>
<td>$392</td>
<td>$248 / $30</td>
<td>$278</td>
</tr>
<tr>
<td>Device</td>
<td>$84 / $18</td>
<td>$102</td>
<td>$710 / $110</td>
<td>$820</td>
</tr>
<tr>
<td>Total</td>
<td>$3,628 / $51</td>
<td>$3,679</td>
<td>$3,829 / $516</td>
<td>$4,345</td>
</tr>
</tbody>
</table>
VCs Are 2x More Likely to Participate in Cross-Border Deals than CVCs

In the past three years, China-based venture capital firms (VCs) have been more active within biopharma than any other healthcare sector, investing in biopharma deals 56% of the time. Dx/Tools trails at 24%, followed by device (14%) and healthtech (6%).

Of the investors on this page, six of the seven VCs have led at least one round for a company based in either the US or Europe. Likewise, of the six corporate investors, each has led a round for a US/European company in the last three years.

VCs are more apt to lead a round than corporate venture capital firms (CVCs), with VCs leading a staggering 50% of cross-border healthcare investments. On the other hand, CVCs lead roughly one out of every four rounds.

China’s cross-border investors fund both Series A and later-stage deals but seem more keen on investing in later-stage companies. In fact, China-based investors who participate in US and European rounds tend to invest in later-stage deals 73% of the time.

For corporate investors, Lilly Asia and WuXi follow the same trends as VCs, while tech investors, such as Tencent and Baidu, prefer dx/tools and have been equally involved in Series A and later-stage rounds.

Most Active China Investors into US and European Venture-Backed Companies

<table>
<thead>
<tr>
<th>Number of Deals (2018–2020)</th>
<th>Venture Capital</th>
<th>Corporate Investor</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Qiming</td>
<td>15</td>
</tr>
<tr>
<td>14</td>
<td>Decheng Capital</td>
<td>9</td>
</tr>
<tr>
<td>11</td>
<td>Sequoia Capital</td>
<td>8</td>
</tr>
<tr>
<td>10</td>
<td>6 Dimensions Capital</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>VI Ventures</td>
<td>5</td>
</tr>
<tr>
<td>6*</td>
<td>Cowin Venture</td>
<td>4</td>
</tr>
<tr>
<td>6*</td>
<td>Etong Capital</td>
<td></td>
</tr>
</tbody>
</table>

*Additional investors have the same number of deals but are not included because of space limitations. Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. 2020 financing data are compiled through 8/31/20. Dates of financing rounds subject to change based on add-on investments. Investors must have at least 4 total investments within 2018–2020 to be considered. Corporate parent and corporate venture investment are combined under corporate investor. Source: PitchBook and SVB proprietary data.
**Big Tech’s Interest in the US Wanes; US Tech Remains Focused at Home**

Big Tech* has participated in 135 deals in the global** healthcare innovation ecosystem since 2017. These corporates invest in Series B or later-stage deals 60% of the time.

Of China’s top tech companies – Baidu, Alibaba and Tencent (BAT) – only Baidu and Tencent (BT) have made cross-border investments into US-based healthcare companies. Alibaba has preferred to stay local with its healthcare investments (four deals since 2017).

Seventeen (68%) of the 25 investments that BT has syndicated in US-based companies were in California (sixteen located in the Bay Area). Despite this interest in the US, BT investments have declined in the past two years with only six investments (four Baidu, two Tencent). This fading interest has been due, in part, to the high valuations of US healthcare companies.

The parallel to BAT is the US’s FAAMG, which has focused only on US and European companies since 2017. Facebook and Apple have participated in zero venture-backed financings, and Amazon has been in only one (GRAIL’s $1.2B in Q4 2017).

Since 2017, Microsoft and Google (Alphabet) have focused on their local markets with only one to two investments per year in European companies. Alphabet has participated in 68 US-based rounds with a focus on biopharma (32 deals) and healthtech (21 deals) over dx/tools (13 deals) and device (2 deals).

---

**Notable Healthcare Deals by Most Active Tech Corporates 2017–2020**

<table>
<thead>
<tr>
<th>HQ: US</th>
<th>HQ: China</th>
<th>HQ: US</th>
<th>HQ: China</th>
<th>HQ: Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopharma</td>
<td>Device</td>
<td>Dx/Tools</td>
<td>HealthTech</td>
<td></td>
</tr>
</tbody>
</table>

---

*Big Tech defined as BAT and FAAMG. Financing data include private financings by venture-backed companies that are based in mainland China and Hong Kong. Investor HQ defined from primary investor HQ from PitchBook. Dates of financing rounds subject to change based on add-on investments. 2020 numbers through 8/31/20. Corporate parents include all known subsidiaries and/or VC arms listed on PitchBook. **Global defined as the US, mainland China, Hong Kong and Europe only. ***Company also fits SVB’s categorization for healthtech. Source: PitchBook, SVB proprietary data and SVB analysis.
European Countries lead US-based HC M&A Deals; China Ninth Globally

CFIUS, a committee dedicated to examining the national security implications of foreign investments in the US, has increased its reviews by more than 300% since 2009. FIRMA’s launch in 2018 expanded CFIUS’s scope, allocating an additional $20M/year to CFIUS. We project that nearly 400 transactions will be reviewed by the end of 2020.

CFIUS has been considered a major headwind for China-based investors and it has resulted in at least one well-publicized healthcare divestiture: PatientsLikeMe (healthtech), which allowed patients to share their data with one another. In this specific case, CFIUS forced the company’s majority stakeholder, iCarbonX, to divest its stake, resulting in PatientsLikeMe getting acquired by United Health Group.

However, in terms of healthcare M&A deals by foreign acquirers, globally, China-based acquirers are ranked ninth compared to the rest of the world. Acquirers based in European countries lead US M&A deals, with the top four countries (UK, Ireland, Switzerland and Germany) having acquirers who have bought 71 private healthcare companies since 2016.

While CFIUS concerns may still exist for European-based acquirers, no foreign acquisitions of US dx/tools or device companies have occurred in 2020, and only three healthtech acquisitions were seen.

US VC-Backed M&A Deals by Foreign Acquirers

<table>
<thead>
<tr>
<th>Biopharma</th>
<th>$9.1B</th>
<th>$15.9B</th>
<th>$3.1B</th>
<th>$4.0B</th>
<th>$15.3B</th>
</tr>
</thead>
<tbody>
<tr>
<td>29%</td>
<td>26%</td>
<td>30%</td>
<td>28%</td>
<td>36%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dx/Tools</th>
<th>$435M</th>
<th>$375M</th>
<th>$420M</th>
<th>$42M</th>
</tr>
</thead>
<tbody>
<tr>
<td>23%</td>
<td>27%</td>
<td>31%</td>
<td>28%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Device</th>
<th>$599M</th>
<th>$2.4B</th>
<th>$254M</th>
<th>$136M</th>
</tr>
</thead>
<tbody>
<tr>
<td>21%</td>
<td>44%</td>
<td>18%</td>
<td>17%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HealthTech</th>
<th>$310M</th>
<th>$312M</th>
<th>$2.2B</th>
<th>$5.8B</th>
<th>$158M</th>
</tr>
</thead>
<tbody>
<tr>
<td>6%</td>
<td>19%</td>
<td>18%</td>
<td>12%</td>
<td>8%</td>
<td></td>
</tr>
</tbody>
</table>

Number of US Healthcare M&A Deals by Acquirer Country

2016–2020

<table>
<thead>
<tr>
<th>Biopharma</th>
<th>UK / 46%</th>
<th>Ireland / 63%</th>
<th>Switzerland / 47%</th>
<th>Germany / 25%</th>
<th>Japan / 73%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dx/Tools</td>
<td>4 / 25%</td>
<td>2 / 11%</td>
<td>1 / 7%</td>
<td>2 / 17%</td>
<td>2 / 18%</td>
</tr>
<tr>
<td>Device</td>
<td>6 / 17%</td>
<td>2 / 11%</td>
<td>3 / 20%</td>
<td>6 / 50%</td>
<td>0 / 0%</td>
</tr>
<tr>
<td>HealthTech</td>
<td>3 / 13%</td>
<td>3 / 16%</td>
<td>4 / 27%</td>
<td>2 / 15%</td>
<td>2 / 17%</td>
</tr>
<tr>
<td>Total Deals</td>
<td>24</td>
<td>19</td>
<td>15</td>
<td>13</td>
<td>12</td>
</tr>
</tbody>
</table>

Only includes M&A deals of venture-backed companies that are primarily based in the US, according to PitchBook, and fit SVB’s healthcare categorization. 2020 numbers through 8/31/20. CFIUS stands for the Committee on Foreign Investment in the United States. Source: PitchBook, news articles, SVB proprietary data and SVB analysis.
Venture-backed Public Healthcare Markets
China
China HC Markets Rebound Faster than Nasdaq HC & Europe HC

A) Within a week of the WHO declaring COVID-19 a pandemic, public markets worldwide tumbled. While Nasdaq and European mid/large cap healthcare indices decreased by -24%, China’s showed more resilience (-12%).

B) S&P Biotech (small/mid cap), which is a proxy for late-stage private market performance, has historically outperformed general healthcare indices globally during the first half of the year. However, in 2020, the Shanghai and China healthcare indices have led the rest of the world, which can be attributed to China’s ability to contain COVID-19 and reopen its economy faster than other countries.

C) Unlike the tech sector, which has seen a decline in IPOs in 2020, the healthcare sector has remained resilient with 63 VC-backed companies ($12B+ total IPO proceeds raised) going public on their local exchanges and China exchanges accounting for 22 (35%) of them. Additionally, 2020 is now ahead of 2019, which saw 45 VC-backed companies raise an aggregated $6.5B during the same period.

The biopharma sector still leads other sectors in IPO proceeds raised, accounting for 75% of the total proceeds in each country.

---

2020 data is through 8/31/20. China includes mainland China and Hong Kong. For C) we only considered venture-backed companies that went public on their local exchange and raised at least $25M in proceeds. Schrödinger (US) is counted as a dx/tools IPO, even though it could be considered a healthtech company. For more information on venture-backed healthcare exit activity see SVB’s Mid-Year 2020 report and for more information on the technology markets see SVB’s State of the Markets Q3 report. Source: PitchBook, Capital IQ, news articles and SVB analysis.
Rise of VC-backed Healthcare IPOs with $1B+ Market Caps

The last five years have seen a steady rise of venture-capital backed healthcare IPOs, with 59 current $1B+ venture-backed public companies (roughly double the 30 unicorns observed at the end of 2019). Biopharma leads the cohort with 29 companies, followed by device and dx/tools — each tied at 14 companies — and finally healthtech with two companies.

Currently, the highest-valued venture-backed healthcare company is Shenzhen Mindray Bio-Medical Electronics (device), which IPO’d in 2018 on the Shenzhen Stock Exchange at $7.03 per share and is now up 611% with a market cap of $60B+. WuXi AppTec and WuXi Biologics, both biopharma companies, are next with respective market caps of $37B and $27B.

The COVID-19 pandemic has resulted in healthcare companies across the world repurposing their products or pivoting their business models to provide aid. We identified 19 of the 59 companies (32%) on this page aiding in the fight against COVID-19, with dx/tools leading over biopharma (9 vs. 7).

$1B+ VC-backed Public Companies by IPO Vintage: 59 Companies

<table>
<thead>
<tr>
<th>Biopharma</th>
<th>Device</th>
<th>Dx/Tools</th>
<th>HealthTech</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>14</td>
<td>14</td>
<td>2</td>
</tr>
</tbody>
</table>

2015 (7 IPOs) 2016 (4 IPOs) 2017 (9 IPOs) 2018 (6 IPOs) 2019 (15 IPOs) 2020 (18 IPOs)

*Aiding in the Fight Against COVID-19 includes companies that are repurposing or donating their products to provide some form of aid. 2020 market cap calculated as of 8/31/20 and 2019 market cap calculated as of 12/31/19. 2020 is through 8/31/20. China includes mainland China and Hong Kong. Includes companies that went public on the SEHK, SHSE and SZSE exchanges only and based in mainland China and Hong Kong. Source: PitchBook, Capital IQ, news articles and SVB analysis.

* Aiding in the fight against COVID-19
Local Exchanges Become Viable Options for Entrepreneurs

Mainland China and Hong Kong stock exchanges have been undergoing reform for the past couple of years, which has resulted in them becoming attractive options for private, venture-backed healthcare companies. Since each exchange has undergone reform, there have been 61 venture-backed healthcare companies (47 have $1B+ market caps as of 8/31/20) that have gone public on these markets. Biopharma is the dominant sector on all three exchanges, and it is interesting that the Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market) has yet to see a healthtech company go public on it.

While companies that have gone public on either of these exchanges have a roughly similar time to exit (4–5 years), companies that have gone out on the Hong Kong Stock Exchange (HKEX) have historically been more valuable (1.3x higher pre-money at IPO) and raised 2.4x more with their IPOs than companies going public on the STAR Market.

In 2020, the best post-IPO performance belongs to Chengdu Kanghua (biopharma) with +725%. The company focuses on vaccine development and went public on the ChiNext Market, which is a subsidiary of the Shenzhen Stock Exchange.

Market cap calculated as of 8/31/20, and 2020 is through 8/31/20. IPO date is from Capital IQ unless it was reported in a news article. Our analysis only includes ChiNext, STAR Market and HKEX companies that fit the SVB healthcare categorization, were venture-backed and based in mainland China or Hong Kong. Source: PitchBook, Capital IQ, STAR Market website, news articles, filing documents and SVB analysis.
China Healthcare Outlook: 2020 & Beyond

Predictions for China’s Venture-backed Healthcare Ecosystem

By the end of 2020, total healthcare venture-backed investments in China will surpass 2018’s $8.1B total raised, making it the best year yet, as biopharma continues to lead over the other three healthcare sectors in activity.

Government-led reforms, such as the 4+7 drug procurement program, will continue to accelerate innovation and cement China as a key contributor to the global healthcare innovation ecosystem.

China will continue to see mega/giga rounds ($100M/$1B+ financings), as its total treatable population is projected to become four times the size of the US in 2030. Shanghai and Beijing will establish their positions within the top five global cities for healthcare innovation, further becoming attractive hubs for foreign-trained talent.

The COVID-19 pandemic will cause valuations of US-based healthcare companies to decline in 2H 2020 and 1H 2021, which may result in an increase in cross-border activity within the US venture-backed healthcare ecosystem.

The recently reformed ChiNext Market, STAR Market and HKEX will result in local companies favoring these exchanges over the Nasdaq.
**Glossary**

**SVB Healthcare Sector Definitions**

**Biopharma** defined as companies that are developing their own therapeutic assets; also includes companies developing new technology and discovery platforms pursuing clinical development of internal assets.

**Diagnostics (Dx)/Tools** defined as companies that advance novel life science research and discovery methods, develop unique diagnostic tests and/or create devices that aid in point-of-care diagnostics or treatment decisions.

**HealthTech** defined as companies that are developing tech-enabled products or services to improve patient outcomes and reduce costs.

**Devices** defined as companies that design and manufacture devices that assist in the monitoring, treatment, mitigation or prevention of a disease, disorder or abnormal physical state.

**Deal Descriptions**

**Venture-backed** defined as any company that has at least one known venture capital investor within its private financing deal history and has raised a minimum of $1M.

**Years to Exit** defined as the time from the close of a company’s first institutional round of financing to the exit.

**Corporate Investor**

**Corporate Investor** defined as both corporate venture and parent company investment into venture-backed companies.

**Geography Definitions**

**Europe** defined as Belgium, Denmark, France, Germany, Italy, Luxembourg, Spain, Sweden, United Kingdom and Switzerland.

**China** defined as mainland China and Hong Kong, unless otherwise specified.

**Indication Definitions**

**Neurology** defined as CNS, pain and psychology companies, as well as neuro implant technologies.

**Non-Invasive Monitoring (NIM)** defined as medical data collection through sensors and other technology.

**Dx Tests** defined as proprietary yes/no diagnostic tests.

**Dx Analytics** defined as actionable data analytics to help determine treatment.

**R&D Tools** defined as research equipment/services for biopharma and academia.

**HealthTech Subsector Definitions**

**Provider Operations** defined as companies that provide solutions to increase the efficiency and accuracy of provider-provider, provider-patient interactions.

**Alternative Care** defined as companies that provide primary or specialty care outside of a hospital or private practice.

**Clinical Trial Enablement (CTE)** defined as companies that develop solutions to accelerate drug discovery and the digitization of clinical trials.

**Healthcare Navigation** defined as companies that guide users to relevant providers and/or payers based on their needs.

**Medication Management** defined as companies that aid users in access and adherence to their prescribed medication.

**Wellness & Education** defined as companies that inform users of healthy lifestyle and medical best practices.

For additional information on SVB’s HealthTech definitions, please see our [SVB HealthTech Report](#).
Disclaimers

This material including, without limitation, to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but which have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction.

SPD, SHANGHAI PUDONG DEVELOPMENT BANK, and 浦发银行有限公司 are trademarks, separately and in combination, of Shanghai Pudong Development Bank, Ltd. in China, and are used under license. SPD Silicon Valley Bank is a Sino-U.S. joint-venture bank of Silicon Valley Bank, the California bank subsidiary and commercial banking operation of SVB Financial Group, and Shanghai Pudong Development Bank.

Silicon Valley Bank is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK under No. FC029579. Silicon Valley Bank is authorized and regulated by the California Department of Business Oversight and the United States Federal Reserve Bank; authorized by the Prudential Regulation Authority with number 577295; and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.

Silicon Valley Bank, a public corporation with limited liability (Aktiengesellschaft) under the laws of the U.S. federal state of California, with registered office in Santa Clara, California, U.S.A. is registered with the California Secretary of State under No. C1175907, Chief Executive Officer (Vorstand): Gregory W. Becker, Chairman of the Board of Directors (Aufsichtsratsvorsitzender): Roger F Dunbar.

Silicon Valley Bank Germany Branch is a branch of Silicon Valley Bank. Silicon Valley Bank Germany Branch with registered office in Frankfurt am Main is registered with the local court of Frankfurt am Main under No. HRB 112038, Branch Directors (Geschäftsführer): Oscar C. Jazdowski, John K. Peck. Competent Supervisory Authority: Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany.

Silicon Valley Bank, an authorized foreign bank branch under the Bank Act (Canada).

©2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: S IVB).
About Silicon Valley Bank
For more than 35 years, Silicon Valley Bank has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators.

About SPD Silicon Valley Bank
Headquartered in Shanghai, China, SPD Silicon Valley Bank (SSVB) is a joint venture between Silicon Valley Bank and Shanghai Pudong Development Bank Co., Ltd. The first Sino-US joint venture bank, SSVB is the first technology and innovation bank in China serving innovation companies of all sizes strives to be the most sought-after bank for China’s innovation economy.

See complete disclaimers on previous page.

©2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).